SCHEMBL23590213

SCHEMBL23590213

CCOc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(F)ccc4n3)nc2)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 8/20 0.55
▸ KDM4E B2RXH2 4/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ ALDH1A1 P00352 3/20 0.53
▸ LMNA P02545 2/20 0.53
▸ HPGD P15428 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ TP53 P04637 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ PLA2G2A P14555 1/20 0.51
▸ GAA P10253 1/20 0.48
▸ EIF4A1 P60842 1/20 0.47
▸ HMOX1 P09601 1/20 0.44
▸ CHRNA7 P36544 1/20 0.44
▸ PDE10A Q9Y233 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590076 0.92 DHODH (0.63) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL26074546 0.92 KDM4E (0.52) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL23590289 0.90 KDM4E (0.62) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL23578600 0.90 DHODH (0.59) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL29959049 0.90 DHODH (0.59) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL23590148 0.90 KDM4E (0.51) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL29997485 0.88 DHODH (0.60) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL23590091 0.88 DHODH (0.60) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL23578618 0.87 DHODH (0.67) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL29958903 0.87 DHODH (0.67) DHODHKDM4ESMN1; SMN2HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
US-20230109418-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2023-04-06 — — US disclosed
WO-2023278778-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-01-05 — — WO disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021133831-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885KDM4E 1396/4885SMN1; SMN2 3677/4885
US-20230109418-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DDO, DLD DHODH 1/4885KDM4E 992/4885SMN1; SMN2 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback